Table 2.

Clinical outcomes in patients with wild‐type transthyretin amyloid cardiomyopathy in each group

	Entire cohort (n = 180)		Propensity score‐matched cohort (n = 66)
	Treatment group (n = 125)	Treatment‐naïve group (n = 55)	Treatment group (n = 33)	Treatment‐naïve group (n = 33)
Primary endpoint: All‐cause death	10 (8%)	40 (73%)	6 (18%)	22 (67%)
Cardiovascular death	9	35	6	19
Non‐cardiovascular death	1	5	0	3
Secondary endpoint: Heart failure hospitalization	21 (17%)	37 (67%)	10 (30%)	22 (67%)
Median (IQR) follow‐up duration (months)	21 (10–31)	27 (16–48)	35 (24–40)	40 (20–56)

Abbreviation: IQR, interquartile range.